Financial Shenanigans

Financial Shenanigans — Molina Healthcare (MOH)

The numbers look like an MCO caught in an industry-wide medical-cost shock — not a company stretching accounting to hide deterioration. The 2025 collapse was real, transparent, and pre-announced; earnings, cash flow, and key metrics moved in the same direction, which is what honest distress looks like. Two judgment areas — IBNP reserve flexibility and the choice to fund a $1.0B buyback with debt while operating cash flow turned negative — keep this off "Clean" and inside "Watch."

Verdict and the two things that matter

Top concern (yellow). Operating cash flow turned negative ($535M used) in FY2025 while GAAP net income was still positive ($472M). The 3-year accrual pattern — CFO that ran 0.55x of net income in FY2024 and then 1.13x negative in FY2025 — is the loudest forensic signal in the file. The disclosed mechanism (timing of government-agency receivables, MLR rebate/risk-corridor settlements, Marketplace risk-adjustment payables, tax timing) is plausible for a managed Medicaid book under a cost trend shock, but it means earnings persistently lead cash by a wide margin and the gap has now flipped against the company.

Second concern (yellow). The reserve cushion is shrinking. Favorable prior-year reserve development fell from $675M (FY2024) to $98M (FY2025) — roughly $577M of the year-over-year medical-margin deterioration was simply the absence of last year's release. Days in claims payable held at 47 (vs 48), so the company is not aggressively drawing reserves, but FY2023–FY2024 earnings were structurally supported by these releases. The pattern is permissible insurance accounting; it is also exactly the line item where managed care income can be smoothed, and investors should treat the FY2023/FY2024 EPS print as quality-adjusted downward.

The cleanest piece of offsetting evidence. Compensation outcomes match the bad results: zero 2025 cash bonus, full forfeiture of the 2023 PSU tranche, and the 2024 CEO/CFO special grants are now expected to vest at $0. The clawback machinery worked. Combined with consistent disclosure (the FY2025 release pre-announced the $2.00/share retroactive premium hit and the Q4 operating loss), the governance and incentive environment is not pushing management toward shenanigans — it has already taken the pain.

What would change the grade. A material FY2026 unfavorable prior-year reserve development (i.e., FY2025 reserves proving inadequate) would push the grade to Elevated by confirming that the company's IBNP estimate was understated when EPS most needed support. A clean Q1–Q2 FY2026 MCR sequencing back toward 88–89% range would push the grade toward Clean.

The 13-category scorecard

Six yellow flags, no reds, seven greens. The yellows cluster in the cash-flow family (CF3, CF4) and the IBNP reserve / one-time-item area (EM3, EM5) and the non-GAAP gap (KM1). The income statement, balance-sheet metric hygiene, and revenue recognition come back clean.

Earnings-quality vs cash-flow quality — the contradiction worth knowing

The bar chart tells the forensic story in one frame. From FY2020–FY2023 CFO ran above net income — the kind of pattern that flags a reserve-cushioned earnings stream. In FY2024 CFO halved while net income hit a high, and in FY2025 CFO collapsed outright. Over the eight-year window the cumulative gap between net income ($5,310M) and CFO ($5,681M) ties out tolerably — which means MOH has not been chronically overstating earnings; rather, the timing between accrued revenue/expenses and government-agency cash has stretched.

The FY2024 reading of 0.55x was the early warning that earnings leadership had already weakened a full year before the headline collapse. A PM reading the FY2024 10-K should have flagged this — CFO dropped 61% YoY while net income rose 8%.

MCR is the engine — and it ran hot through FY2025

The cost ratio rose every quarter from Q2 2025 through Q4 2025, peaking at 89.1% in Q4 (consolidated reported MCR was 91.7% on a premium-only base). Q1 2026 reverted to 85.9%, which is consistent with management's framing — the cost trend was a real industry shock, not a hidden accounting reset. Management's pre-announcement of the $2.00/share retroactive California Medicaid premium adjustment in Q4 is the kind of disclosure that distances this from a shenanigans pattern.

Working capital was the entire CFO swing

Two thirds of the year-over-year CFO swing came from two lines that move together when government-agency timing inverts: receivables grew $234M (collection delay on MLR rebates and risk-adjustment items) and the medical claims payable line shrank $238M (faster payouts as utilization rose). The "other working capital / settlements" residual — which includes minimum-MLR settlements, marketplace risk-adjustment payables, and tax timing — was roughly flat year over year but the headline moved because the AR and AP lines flipped the wrong way at the same time. This is the mechanism behind the headline; it is disclosed; it is not opaque.

Reserve-development cushion — the line to watch

The reserve-release column is the single most informative forensic line in MOH's financials. FY2023 benefited from $441M of favorable releases, FY2024 from $675M; both years' earnings were structurally supported. FY2025 dropped to $98M — i.e., the cushion was almost gone, and most of the YoY medical-margin contraction was the disappearance of that benefit, not a new reserve overshoot. Forensic interpretation: this is consistent with a company that built conservative IBNP estimates in 2022/2023, released into 2024, and is now reserving tighter in 2025. The next two prints — Q1/Q2 FY2026 prior-year development — will be the diagnostic. Any unfavorable development means the FY2025 IBNP was light.

Capital allocation through the downturn

Management spent $1.0B on buybacks in both FY2024 and FY2025 — concentrated in two $500M transactions during 2025 (Q1 and Q3) — and funded the FY2025 program with $1.94B of fresh debt issuance against $1.1B repaid. Long-term debt rose from $2.92B to $3.77B (+29%). This is not a shenanigan but it is an aggressive capital-allocation choice into a known earnings shock, and it is the reason management amended its credit agreement on February 4, 2026 to temporarily reduce the minimum Interest Coverage Ratio covenant to 1.75:1.00 for fiscal quarters ending March 31, 2026 through December 31, 2026, stepping back up to 2.75:1.00 by Q3 2027. Covenant relief is a stress signal that an investor should treat as a yellow flag regardless of the accounting picture.

Non-GAAP hygiene

The non-GAAP gap widened from ~10% in FY2024 to ~24% in FY2025. The adjustments are predominantly acquisition-related amortization, certain non-recurring items, and tax effects — definitional reconciliation is disclosed. The single biggest "non-GAAP shenanigan" red flag — adjustments redefined year over year so today's "adjusted" is not last year's "adjusted" — is not present here. The bigger metric-story signal is that FY2025 adjusted EPS of $11.03 missed initial guidance of $24.50 by 55% — the guidance machinery was either materially wrong or willfully optimistic. Management's pay-for-performance design produced a zero short-term bonus, which is the proper response.

Soft-asset accumulation traces to disclosed M&A

Goodwill rose 11.5x between FY2018 and FY2025, every step traceable to a disclosed transaction (Magellan Complete Care, AgeWell, Cigna Texas Medicaid, Bright Health Medicare, MyChoice Wisconsin, ConnectiCare). Goodwill is now 14.1% of total assets. There has been no impairment charge through FY2025 despite the earnings collapse; FY2026 will be the first stress test of those carrying values under the new run-rate. A goodwill impairment in FY2026 would not be a shenanigan but it would be a useful forensic data point about prior-year purchase-price discipline.

Governance, audit, and incentives

The breeding-ground assessment dampens rather than amplifies the accounting risk. Founder family is no longer in management; auditor tenure is long but unremarkable for an S&P 500 health insurer; compensation outcomes matched results; related-party exposure is trivially small. The single governance yellow flag — covenant relief — is an operating-stress signal, not an integrity signal. The 2025 say-on-pay failure was about the size of the fall-2024 retention grants, not their structure; those grants are now expected to vest at $0.

Sector lens — managed Medicaid checklist

Reserve development: disclosed, slipping cushion. Days in claims payable: 47 (stable). MLR by segment: disclosed; all three segments above long-term target. Risk corridors / minimum MLR: MD&A names these as the cash-flow timing items behind the CFO swing. Marketplace risk adjustment: disclosed; reconciliation items affected Q4. Statutory capital: subsidiaries above $3.1B minimum; $985M dividended to parent in FY2025. Investment portfolio: $8.6B at AA- average rating, $20M net unrealized gain at YE FY2025 vs $75M loss YE FY2024 — fair-value picture improved. None of these flags a shenanigan; the relevant signal is the prior-year reserve development trend and the CFO timing.

Per-flag attribute table

What to underwrite next

Five things to watch through FY2026, ranked by forensic value:

1. Prior-year reserve development in Q1 and Q2 FY2026. If FY2025 reserves prove inadequate (i.e., unfavorable development emerges), upgrade to Elevated. If modestly favorable, the FY2025 stress was a real-world cost trend shock and the grade can move toward Clean. Watch line: "Components of medical care costs related to: Prior year" in the medical claims and benefits payable rollforward.

2. CFO / Net Income for full-year FY2026. Management is guiding to adjusted EPS of at least $5.00 (vs $11.03 FY2025) — earnings are expected to fall again. CFO should track at least 0.8x of net income without the help of acquired working capital. A second consecutive negative CFO year would be a material grade downgrade.

3. Interest Coverage Ratio under the amended Credit Agreement. The 1.75x covenant floor is binding through Q4 FY2026; trailing-twelve-month interest expense is rising and adjusted EBIT is falling. A covenant cushion below 0.5x at any quarter end would be a significant Elevated trigger.

4. California Medicaid retroactive premium item disposition in FY2026. The Q4 FY2025 charge was disclosed as retroactive; if further retroactive adjustments appear in 1H FY2026 it implies the FY2025 hit was understated. Specific watch: any mention of California rate-true-up in Q1/Q2 FY2026 earnings releases.

5. Goodwill carrying value review. FY2026 will be the first annual impairment test under materially reduced run-rate earnings. Any goodwill impairment charge — particularly tied to ConnectiCare, Bright, or MyChoice — would be a useful forensic data point about prior purchase-price discipline, not a shenanigan in itself.

Bottom line. The accounting risk at MOH is a position-sizing item, not a thesis breaker. The forensic file does not change the case for or against ownership; it changes how much margin of safety a PM should demand against the FY2026 adjusted-EPS guidance of $5.00 and the embedded FY2027 recovery story. Trust the disclosed numbers, discount the adjusted figures by the ~24% non-GAAP gap when stress-testing, and treat the IBNP reserving line as the single most important diagnostic in the next two quarterly filings.